Filtered By:
Drug: Taxotere
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 2210 results found since Jan 2013.
Aminosteroid RM-581 Decreases Cell Proliferation of All Breast Cancer Molecular Subtypes, Alone and in Combination with Breast Cancer Treatments
This study demonstrates that RM-581 could be effective for the treatment of BC, especially TNBC.PMID:37445276 | DOI:10.3390/jcm12134241
Source: Clinical Genitourinary Cancer - July 14, 2023 Category: Cancer & Oncology Authors: Anna Burguin Jenny Roy Genevi ève Ouellette Ren é Maltais Juliette Bherer Caroline Diorio Donald Poirier Francine Durocher Source Type: research
Aldehyde dehydrogenase 2 rs671 genetic polymorphisms are associated with chemotherapy-induced nausea and vomiting
CONCLUSION: ALDH2 gene mutation at rs671 is a risk factor contributing to the occurrence of CINV, and understanding of the underlying mechanism may help to more effectively control the occurrence of CINV.PMID:37439175 | PMC:PMC10339303 | DOI:10.12122/j.issn.1673-4254.2023.06.18
Source: Journal of Southern Medical University - July 13, 2023 Category: Universities & Medical Training Authors: Q Yang X Liu Y Jiang J Ma Source Type: research
Sequential intravesical gemcitabine and docetaxel for treatment-na ïve and previously treated intermediate-risk nonmuscle invasive bladder cancer
CONCLUSIONS: In this retrospective review of a heterogenous population of patients with intermediate-risk NMIBC, Gem/Doce was an effective and well-tolerated adjuvant therapy. Further prospective evaluation in this setting is needed.PMID:37442741 | DOI:10.1016/j.urolonc.2023.06.017
Source: Urologic Oncology - July 13, 2023 Category: Urology & Nephrology Authors: Ian M McElree Joanna Orzel Reid Stubbee Ryan L Steinberg Sarah L Mott Michael A O'Donnell Vignesh T Packiam Source Type: research
Aldehyde dehydrogenase 2 rs671 genetic polymorphisms are associated with chemotherapy-induced nausea and vomiting
CONCLUSION: ALDH2 gene mutation at rs671 is a risk factor contributing to the occurrence of CINV, and understanding of the underlying mechanism may help to more effectively control the occurrence of CINV.PMID:37439175 | PMC:PMC10339303 | DOI:10.12122/j.issn.1673-4254.2023.06.18
Source: Journal of Southern Medical University - July 13, 2023 Category: Universities & Medical Training Authors: Q Yang X Liu Y Jiang J Ma Source Type: research
Sequential intravesical gemcitabine and docetaxel for treatment-na ïve and previously treated intermediate-risk nonmuscle invasive bladder cancer
CONCLUSIONS: In this retrospective review of a heterogenous population of patients with intermediate-risk NMIBC, Gem/Doce was an effective and well-tolerated adjuvant therapy. Further prospective evaluation in this setting is needed.PMID:37442741 | DOI:10.1016/j.urolonc.2023.06.017
Source: Urologic Oncology - July 13, 2023 Category: Urology & Nephrology Authors: Ian M McElree Joanna Orzel Reid Stubbee Ryan L Steinberg Sarah L Mott Michael A O'Donnell Vignesh T Packiam Source Type: research
Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials
Conclusion: Compared with ADT alone, neoadjuvant therapy with ADT plus docetaxel or abiraterone could achieve better pathological outcomes (pCR or MRD) for very-high-risk localized prostate cancer. The ADT plus abiraterone group showed longer bPFS than ADT alone. The combination regimens were tolerable.PMID:37435500 | PMC:PMC10331422 | DOI:10.3389/fphar.2023.1217303
Source: Cancer Control - July 12, 2023 Category: Cancer & Oncology Authors: Junlong Zhuang Yuwen Wang Shun Zhang Yao Fu Haifeng Huang Xiaoyu Lyu Shiwei Zhang Giancarlo Marra Linfeng Xu Xuefeng Qiu Hongqian Guo Source Type: research
Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials
CONCLUSIONS: In early breast cancer patients treated with adjuvant chemotherapy, baseline severe obesity was significantly linked to worse DFS and OS, and a BMI loss over 10% from baseline to post-adjuvant chemotherapy also negatively affected OS. Moreover, the prognostic role of BMI might differ between docetaxel-based and non-docetaxel-based groups.PMID:37429049 | DOI:10.1016/j.breast.2023.07.002
Source: Breast - July 10, 2023 Category: Cancer & Oncology Authors: Haizhu Chen Xiaoyan Qian Yunxia Tao Daquan Wang Ying Wang Yunfang Yu Herui Yao Source Type: research
